COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
MIT Solve Announces 2024 Global Challenges and Indigenous Communities Fellowship
MIT Solve announces over $1 million in prize funding for 2024 Global Challenges and Indigenous Communities Fellowship. Innovators can submit solutions till April 18 to address pressing global issues. Selected solvers to pitch at UN General Assembly Week and receive funding -
COMMUNIQUÉ DE PRESSE
Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Moderna, Inc. to report Q4 and full year 2023 financial results and provide corporate update in live conference call and webcast on February 22, 2024. Archived webcast available for one year -
COMMUNIQUÉ DE PRESSE
U.S. Polo Assn. Celebrates the United States Winter Polo Season as Official Sponsor of the USPA National Polo Center (NPC)
U.S. Polo Assn. celebrates new sponsorship at USPA National Polo Center, with branded updates, MVP Lounge, and dedicated polo events. Commitment to heritage and fan experience -
COMMUNIQUÉ DE PRESSE
AmplifyBio Celebrates Grand Opening of Manufacturing Enablement Center in New Albany, Ohio
AmplifyBio celebrates successful grand opening of AMEC, showcasing manufacturing suites and operating models for advanced therapies. Executives and key speakers highlight the milestone event's significance -
COMMUNIQUÉ DE PRESSE
'Innovation through partnerships: Your Family Entertainment AG integrates artificial intelligence (AI) into its corporate strategy'
Your Family Entertainment AG integrates artificial intelligence (AI) into its corporate strategy to revolutionize profitability through localization and language adaptation, quality improvement of existing content, and efficient content analysis. Partnerships with Adesso SE, Lalamu Studio, Relativity GmbH, and WTS Advisory AG strengthen the company's position as a pioneer in child- and family-friendly entertainment -
-
COMMUNIQUÉ DE PRESSE
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
NanoViricides, Inc. reports on the strong safety and tolerability of NV-CoV-2 oral drug products, showcasing their potential for long-term success and broad-spectrum antiviral capabilities, including against RSV and Smallpox-like viruses -
COMMUNIQUÉ DE PRESSE
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA declares the total number of shares, theoretical voting rights, and net voting rights making up the issued capital, in accordance with regulatory requirements -
